Annual reportSep 2026
Sep 2026 · Updates 10 Sep - 6th AGM on September 18, 2026; annual report FY2025-26 shared, with KYC and email update reminder.
Source: Nse
Influx Healthtech Ltd. (INFLUX)
SME CapPharma stocks · SME cap · NSE
Influx Healthtech is a CDMO specializing in nutraceuticals, cosmetics, pet care, and homecare, offering end-to-end services from product development to regulatory support. Operates 4 facilities in Palghar, Maharashtra, with 3,400+ products and 700+ clients globally. Listed on NSE Emerge in June 2025.
₹262.65
+3.15 · +1.21%
Market cap ₹608 Cr
Data qualityVerify one data layerQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals18 Oct 2026 · screener
Latest result20 May, 10:03 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags04 Oct 2026
Coverage9/14 · 64%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
71BullishSMA20 -5.9% / mo · MACD + · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 52
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
INFLUXD candles · FIT view+4.5%Latest close ₹262.65 on 2026-10-21
Bar
+2.6%
RSI
44
MACD hist
0.00
52W pos
64%
2026-10-21O ₹256.00H ₹272.00L ₹245.30C ₹262.65Vol 53,400 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
INFLUXNifty PharmaNifty 500
- INFLUX
- -12.5%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- -6.0 pp
Chart stats
21 Oct 2026- From 52W high
- -16.6%
- 52W range position
- 65%
- ATR (14)
- 5.2%
- Volume vs 20D
- 1.74x
- Avg traded value
- ₹0.9 Cr
- 20D price channel
- ₹240 - ₹290
₹315
₹166 - ₹315
₹13.6
Latest completed session
20-session average
41.4% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · OVERVALUED27
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Pending data—
Revenue NDF · PAT NDF YoY
Technical
Bullish71
Price trend and sector-relative-strength timing.
Valuation
Legacy model-300.7%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence65
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 31 Mar 2026
Pending dataYoY comparison unavailable - result verdict pending data
Filed 31 Mar 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹80 Cr | NDF | +19.4% |
| EBITDA | ₹15 Cr | NDF | +0.0% |
| Operating margin | 19.0% | NDF | -300 bps |
| PAT | ₹11 Cr | NDF | +10.0% |
| PAT margin | 13.8% | NDF | -118 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 31.80
- P/B
- 6.05
- EV/EBITDA
- 17.88
- Market Cap
- 608.00Cr
Profitability
- ROE
- 19.00%
- ROCE
- —
- ROA
- 16.94%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- —
- EPS 5Y
- —
- Revenue 3Y
- —
- EPS 3Y
- —
Balance Sheet
- Debt/Equity
- 0.00
- Interest Coverage
- —
- Altman Z
- 9.16
- Book Value
- 43.50
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- 4.00 Cr
- EPS TTM
- 8.87
Shareholding
- Promoter Hold
- 73.53%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 65%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 80.0+19.4% vs prev
Net Profit
₹ CrLatest: 11.0+10.0% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
NeutralTrend is undirectional — long-term uptrend intact. RSI 44.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~6.3% over last month) — short-term momentum negative.
- RSI(14) at 44 — sideways, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 17% off 52W high · 56% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
82
RS percentile
Stage 1 Base / Transition
1M return
-4.9%
3M return
-12.5%
6M return
-4.7%
1Y return
+50.1%
RS 1D
+2
RS 20D
-2
Sector rank
#1
Industry rank
#5
Stage evidence
- Price is within 1.7% of the 30-week proxy.
- The 30-week proxy changed +2.9% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price above
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 152.79+2.16%
RS vs Nifty 500153
Valuation & peers
U-Score 27 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 27 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation2/30
Growth3/25
Quality9/20
Balance Sheet9/15
Cash Flow1/10
Piotroski
6/9 (+3)
Penalties
0
Raw sum
27
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
27/100 · legacy band OVERVALUED
Positive drivers
- Balance sheet contributes 9/15 to the score.
- Quality contributes 9/20 to the score.
- Growth contributes 3/25 to the score.
Main drags
- Fair-value margin of safety is negative at -300.7%.
- Valuation is weaker at 2/30; verify the latest quarterly trend.
- Cash flow is weaker at 1/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
31.8
PB
6.0
EV/EBITDA
17.9
ROE
19.0%
ROCE
—
FCF Yield
—
Debt/Equity
0.0
MoS
-300.7%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
27
Previous: 27
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-300.7%
Previous: -295.9%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
15
15
15
16
15
15
16
16
27
27
27
27
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹93.17
-181.9% MoS
Growth-justified P/E
7.4
Growth-justified Value
₹65.55
-300.7% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
NURECA
Small
Nureca Limited
Medical Devices
match 161
23
65.9
1.1%
-7143%
OVERVALUED
OSELDEVICE
SME
Osel Devices Ltd.
Medical Devices
match 141
60
21.1
18.7%
+53%
UNDERVALUED
VILINBIO
SME
VILIN BIO MED LTD.
Medical Devices
match 135
31
44.6
7.5%
+7%
OVERVALUED
GML
SME
Galaxy Medicare Ltd.
Medical Devices
match 131
67
8.3
10.8%
+81%
UNDERVALUED
POLYMED
Large
Poly Medicure Limited
Medical Devices
match 120
32
50.1
9.0%
-11%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Where growth can come from, and what can break the case
Thesis intactReviewed 2026-08-18T02:12:09.213Z
Management commentary snapshot
FY26 revenue grew 40% YoY to INR 146.8 crs, with EBITDA up 45% to INR 29.9 crs and PAT up 54% to INR 20.5 crs. Margins expanded, but RoE and capacity utilization declined. Company secured FSSAI license for a new facility and invested in tablet capacity expansion.
Influx Healthtech delivered strong financial growth in FY26, driven by its core nutraceuticals segment and strategic capacity expansions. While RoE and capacity utilization declined, significant planned CapEx and new product launches, coupled with positive industry tailwinds for CDMO and nutraceuticals, support continued growth. Management's FY27 guidance indicates sustained momentum.
Current business mix
Revenue Mix – FY26 (%)
Latest issuer-disclosed distribution across 4 reported categories.
Nutraceuticals90.0%
Cosmetics5.0%
Ayurvedic4.0%
Veterinary & Homecare1.0%
Growth engines
Nutraceuticals Segment Growth
Nutraceuticals revenue grew 40.3% YoY in FY26, comprising 90% of total revenue.
New Product Development
Introduced Quick Snap technology, MMTC technology, and functional beverages in FY26, expanding product portfolio.
Capacity Expansion
Invested ₹60 Lakhs to boost tablet capacity. Planned CapEx in nutraceuticals, cosmetics, veterinary & homecare segments.
Geographic Expansion
Received clearance to expand into the Tanzania market, increasing export reach to 36 countries.
Capacity and execution
Tablet Capacity Expansion
Invested ₹60 Lakhs to boost tablet capacity from 20,000 bottles to 30,000-35,000 bottles per day.
Planned CapEx for H2FY27
Planned CapEx in nutraceuticals, cosmetics, veterinary & homecare segments to go live by H2FY27.
Nutraceutical CDMO Facility Expansion
Reallocated IPO funds for enhanced construction cost, expanding nutraceutical CDMO facility from ~35,000 to 75,000 sq. ft.
New Production Lines Ordered
Ordered automated beverage manufacturing line (10,000 bottles/hour) and high-capacity pet food production line (1,000 kg/hour).
Tailwinds
Indian CDMO Industry Growth
Indian CDMO industry is projected to grow at 13.8% CAGR, 2x the global industry's 7.2% CAGR.
Strategic Shift Towards Outsourcing
Pharma firms are increasingly outsourcing to CDMOs for cost savings and specialized expertise.
Indian Nutraceutical Industry Opportunity
India's nutraceutical industry is a $76 BN opportunity, projected to grow at 10.0% CAGR.
Rising Health Consciousness
Lifestyle shifts and rising health awareness are driving increased demand for nutraceutical products.
Risk radar
Declining Return on Equity (RoE)
RoE decreased to 20.4% in FY26 from 37.0% in FY25.
Reduced Capacity Utilization
Capacity utilization fell to 70% in FY26 from 89% in FY25, despite capacity additions.
Negative Shift in Cash Conversion Cycle
Cash Conversion Cycle moved from -23 days in FY25 to 64 days in FY26.
Decreased F&D Investment
F&D investment decreased to INR 5 lakhs in FY26 from INR 24 lakhs in FY25, potentially impacting future innovation.
Management accountability
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Analyst reading lens
Compare YOY
The presentation primarily focuses on annual performance (FY26 vs FY25) and half-yearly (H2 FY26 vs H2 FY25) comparisons, which are more relevant for assessing growth trends in a manufacturing business with potential seasonality and project execution.
Sector KPIs management disclosed
Nutraceuticals Revenue Growth
Nutraceuticals revenue grew 40.3% YoY to INR 131.9 crs in FY26.
Export Countries
Export countries increased from 11 in FY25 to 36 in FY26. Received clearance to expand into the Tanzania market.
New Product Introductions
Introduced Quick Snap technology, MMTC technology, and functional beverages in FY26.
Regulatory Approvals
Secured a 5-year FSSAI license for the new rented facility. Received GMP compliance approval for Tanzania expansion.
Management forward view
FY27 Growth Guidance
Management provided FY27 growth guidance of 25-30% with similar margins.
Commercialization of New Lines
Plans to commercialize automated beverage line and high-capacity pet production line.
CapEx Go-Live Timeline
Planned CapEx in nutraceuticals, cosmetics, veterinary & homecare segments to go live by H2FY27.
Thesis monitor
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| FY27 Revenue Growth | 40% (FY26) | Achieving management's 25-30% guidance. |
| EBITDA Margin | 20.3% (FY26) | Maintaining similar margins as guided by management. |
| Capacity Utilization | 70% (FY26) | Improvement in utilization rates post new capacity commissioning. |
| Return on Equity (RoE) | 20.4% (FY26) | Reversal of the declining trend in RoE. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust Score
65Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 45th percentile of the scored universe and 33rd percentile within Pharma. Main check: cash conversion is weak at 43/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
5 docs text-extracted · 2 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
45th percentile
overall median 67 · Pharma: 33rd pctile, median 70 · SME: 56th pctile, median 64
Evidence depth
Financial-only
5 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
43
weak · profit to cash conversion
Balance sheet
80
strong · leverage and solvency
Discipline
60
acceptable · capital discipline
Results
63
acceptable · quarterly consistency
Trust positives
- ▸Promoter holding is 73.5%.
- ▸Promoter pledge is zero.
- ▸Debt/equity is 0.00.
- ▸OPM spread across recent quarters is 3%.
Trust risks
- ▸Only 0 years of positive FCF.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Influx Healthtech Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual reportSep 2026
Sep 2026 · Shareholders meeting 26 Aug - Influx Healthtech issued FY2025-26 annual report and AGM notice for September 18, 2026.
Source: Nse
Investor presentationMay 2026
May 2026 · PPT
Source: Nse
Concall transcriptMay 2026
May 2026 · Transcript
Source: Nse
Annual report
Annual Report 2026
Source: Nse
Concall transcriptNov 2025
Nov 2025 · Transcript
Source: Nse
Investor presentationNov 2025
Nov 2025 · PPT
Source: Nse
Investor presentationAug 2025
Aug 2025 · PPT
Source: Nse
Annual report
Annual Report 2025
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.